POTENTIAL OF A NOVEL ANTI-PLATELET APTAMER IN OPTIMIZING ANTITHROMBOTIC

深入和可控的抗凝在大量临床手术中是必不可少的，包括经皮和外科血管重建术（PCI和CABG），主动脉手术和其他血管干预。各种血栓性疾病，如急性冠状动脉综合征、肺栓塞或深静脉血栓形成，也需要立即抗凝治疗。所有这些干预和治疗的重大风险和副作用包括导致脑血管或心血管损害的深度出血或血栓形成。这些结果的临床和财务影响可能是深远的，并与住院时间延长、生活质量下降和卫生保健资源增加有关

Profound and controllable anticoagulation is essential during a large number of clinical procedures including percutaneous and surgical revascularization procedures (PCI and CABG), aortic surgery and other vascular interventions. Immediate anticoagulation therapy is also required in a variety of thrombotic diseases such as acute coronary syndromes, pulmonary embolism or deep vein thrombosis. Significant risks and side effects of all of these interventions and therapies include profound bleeding or thrombosis leading to cerebrovascular or cardiovascular compromise. The clinical and financial implications of these outcomes can be profound and are associated with prolonged hospitalization, reduced quality of life, and increased health-care resource utilization. The proposed work extends the basic discoveries of novel therapeutic anticoagulant aptamer/antidote pairs. We believe that a crucial next step in the translation of these agents to clinical practice is the testing in predictive in vitro and animal models such as those we will employ in this project. The proposed work will reveal whether this innovative therapeutic strategy can provide superior anticoagulation in prothrombotic environments, while avoiding undesired effects such as bleeding, platelet dysfunction, systemic inflammation and impaired wound healing.